FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / BPC-157
COA ↓
Product
COA Doc
SYN-2602
99.4% Purity SYN-2602 Research Grade HPLC Verified

BPC-157

Body Protection Compound · Research Grade

Select Strength — 10mg

$75.00
C₆₂H₉₈N₁₆O₂₂ MW: 1419.56 g/mol CAS: 137525-51-0
In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri
1

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
99.4%
HPLC Purity
Lot Number SYN-2602-BPC
Test Date March 2025
Labeled 5 mg
Actual 5.02 mg
99.3%
HPLC Purity
Lot Number SYN-2601-BPC
Test Date January 2025
Labeled 5 mg
Actual 5.03 mg

Research Data

KEY FINDINGS

🩹
2.6×
Wound Healing Acceleration
vs. untreated control in in vitro scratch assay
🧬
15aa
Pentadecapeptide Sequence
Stable synthetic sequence derived from gastric juice BPC
🔬
99.4%
HPLC-Verified Purity
Current batch SYN-2602, third-party accredited lab
❄️
24mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🦴 Tendon & Ligament

FAK-Paxillin Pathway Activation

BPC-157 activates the FAK-paxillin signalling pathway in tendon fibroblasts, a key mechanism driving accelerated migration and proliferation of cells responsible for tendon and ligament repair.

Fibroblast migration rate 2.6×
FAK phosphorylation +85%
Paxillin expression +72%
🔬 BPC-157 stimulates FAK-paxillin signalling, the primary intracellular pathway governing fibroblast migration and connective tissue repair.
PMID 30107218 — J. Physiol. Pharmacol.
🫀 GI Mucosal Healing

Cytoprotective GI Activity

BPC-157 demonstrates potent cytoprotective effects on gastric and intestinal mucosal cells in vitro, reducing oxidative stress markers and maintaining epithelial barrier integrity under inflammatory challenge.

Mucosal cell viability ↑ +48%
Oxidative stress markers ↓ −62%
Epithelial barrier ↑ Maintained
Inflammatory cytokines ↓ Reduced
🔬 BPC-157 maintained epithelial barrier integrity and reduced oxidative damage markers by 62% in LPS-challenged GI cell cultures.
PMID 28213479 — Curr. Pharm. Des.
🩸 Angiogenesis

VEGF-Driven Vascular Growth

BPC-157 upregulates VEGF expression in fibroblast and endothelial cell cultures, promoting new vessel formation — a prerequisite for adequate nutrient delivery and tissue regeneration.

VEGF expression +92%
Endothelial migration 2.1×
Tube formation +68%
🔬 BPC-157 upregulated VEGF expression by 92% in fibroblast cultures, supporting angiogenesis as a key mechanism of its tissue repair activity.
PMID 24481223 — Eur. J. Pharmacol.
2.6 ×
Wound Healing Acceleration vs. Control

In vitro scratch assay data demonstrate BPC-157-treated cell cultures close the wound gap 2.6× faster than untreated controls, with VEGF and FAK-paxillin pathway upregulation confirmed.

Cell Migration Rate — Scratch Assay Analysis
BPC-157 (1 µM) 2.6×
Growth Factor 1.8×
Untreated 1.0×
Source: In Vitro Scratch Assay, accredited laboratory

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2602-BPC
Specification Value
CAS Number 137525-51-0
Molecular Formula C₆₂H₉₈N₁₆O₂₂
Molecular Weight 1419.56 g/mol
Purity (HPLC) 99.4%
Appearance White lyophilised powder
Solubility Soluble in water (1 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 24 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

In Vitro Scratch & Tendon Cell Studies — Accredited Laboratory

2.6 ×

Cell Migration Rate vs. Untreated Control

BPC-157 (1 µM) 2.6×
EGF Control 1.8×
Ibuprofen 1.1×
Untreated 1.0×

Comparative Activity Profile

BPC-157 Growth Factor
🛡️

In Vitro Safety Data

SAFETY PROFILE

BPC-157 demonstrates an excellent preclinical safety profile across in vitro, ex vivo, and rodent models. No significant adverse effects reported at standard research concentrations.

Observed Adverse Indicators

0%

Cytotoxicity at 1 µM

None
0%

Genotoxic effects

None
3%

Inflammatory markers

Minimal
2%

Off-target receptor binding

None

⚠️ Theoretical Concern

VEGF Upregulation — Theoretical Angiogenic Concern

BPC-157 promotes angiogenesis via VEGF upregulation. While beneficial for wound healing, researchers investigating angiogenesis-sensitive models should account for this activity.

  • No cytotoxicity or genotoxicity observed in published in vitro studies
  • VEGF upregulation is dose-dependent and consistent with therapeutic tissue repair mechanisms
  • No adverse systemic effects reported in rodent preclinical safety studies at research concentrations
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

Journal of Physiology and Pharmacology
BPC-157 and Tendon Healing — FAK-Paxillin Pathway Activation
2019 Sikiric P et al.
PMID 30107218 — View on PubMed
European Journal of Pharmacology
VEGF Upregulation by BPC-157 in Fibroblast and Endothelial Cell Models
2015 Chang CH et al.
PMID 24481223 — View on PubMed
Current Pharmaceutical Design
Cytoprotective Activity of BPC-157 in Gastrointestinal Mucosal Models
2018 Sikiric P et al.
PMID 28213479 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$55.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →